179 related articles for article (PubMed ID: 31730920)
1. Allogeneic Haploidentical Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide in Chronic Lymphocytic Leukemia.
Paul S; Tsai HL; Lowery P; Fuchs EJ; Luznik L; Bolaños-Meade J; Swinnen LJ; Shanbhag S; Wagner-Johnston N; Varadhan R; Ambinder RF; Jones RJ; Gladstone DE
Biol Blood Marrow Transplant; 2020 Mar; 26(3):502-508. PubMed ID: 31730920
[TBL] [Abstract][Full Text] [Related]
2. Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis.
Hamadani M; Zhang MJ; Tang XY; Fei M; Brunstein C; Chhabra S; D'Souza A; Milano F; Phelan R; Saber W; Shaw BE; Weisdorf D; Devine SM; Horowitz MM
Biol Blood Marrow Transplant; 2020 Jul; 26(7):1312-1317. PubMed ID: 32283185
[TBL] [Abstract][Full Text] [Related]
3. Shortened-Duration Immunosuppressive Therapy after Nonmyeloablative, Related HLA-Haploidentical or Unrelated Peripheral Blood Grafts and Post-Transplantation Cyclophosphamide.
DeZern AE; Elmariah H; Zahurak M; Rosner GL; Gladstone DE; Ali SA; Huff CA; Swinnen LJ; Imus P; Borrello I; Wagner-Johnston ND; Ambinder RF; Brodsky RA; Cooke K; Luznik L; Fuchs EJ; Bolaños-Meade J; Jones RJ
Biol Blood Marrow Transplant; 2020 Nov; 26(11):2075-2081. PubMed ID: 32818556
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide for Peripheral T Cell Lymphoma: The Importance of Graft Source.
Sterling CH; Hughes MS; Tsai HL; Yarkony K; Fuchs EJ; Swinnen LJ; Paul S; Bolaños-Meade J; Luznik L; Imus PH; Ali SA; Jain T; Ambinder A; DeZern A; Huff CA; Gocke CB; Varadhan R; Wagner-Johnston N; Jones RJ; Ambinder RF
Transplant Cell Ther; 2023 Apr; 29(4):267.e1-267.e5. PubMed ID: 36549386
[TBL] [Abstract][Full Text] [Related]
5. Post-Transplantation Cyclophosphamide for Graft-versus- Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type. A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
Sahebi F; Eikema DJ; Koster L; Kroger N; Meijer E; van Doesum JA; Rovira M; Koc Y; Angelucci E; Blaise D; Sammassimo S; McDonald A; Arroyo CH; Sanchez JF; Forcade E; Castagna L; Stölzel F; Sanz J; Tischer J; Ciceri F; Valcarcel D; Proia A; Hayden PJ; Beksac M; Yakoub-Agha I; Schönland S
Transplant Cell Ther; 2021 Dec; 27(12):999.e1-999.e10. PubMed ID: 34543768
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Multiple Myeloma.
Ghosh N; Ye X; Tsai HL; Bolaños-Meade J; Fuchs EJ; Luznik L; Swinnen LJ; Gladstone DE; Ambinder RF; Varadhan R; Shanbhag S; Brodsky RA; Borrello IM; Jones RJ; Matsui W; Huff CA
Biol Blood Marrow Transplant; 2017 Nov; 23(11):1903-1909. PubMed ID: 28711728
[TBL] [Abstract][Full Text] [Related]
7. Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis.
Kanakry JA; Kasamon YL; Bolaños-Meade J; Borrello IM; Brodsky RA; Fuchs EJ; Ghosh N; Gladstone DE; Gocke CD; Huff CA; Kanakry CG; Luznik L; Matsui W; Mogri HJ; Swinnen LJ; Symons HJ; Jones RJ; Ambinder RF
Biol Blood Marrow Transplant; 2013 Oct; 19(10):1514-7. PubMed ID: 23871780
[TBL] [Abstract][Full Text] [Related]
8. Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide Using Non-First-Degree Related Donors.
Elmariah H; Kasamon YL; Zahurak M; Macfarlane KW; Tucker N; Rosner GL; Bolaños-Meade J; Fuchs EJ; Wagner-Johnston N; Swinnen LJ; Huff CA; Matsui WH; Gladstone DE; McCurdy SR; Borrello I; Gocke CB; Shanbhag S; Cooke KR; Ali SA; Brodsky RA; DeZern AE; Luznik L; Jones RJ; Ambinder RF
Biol Blood Marrow Transplant; 2018 May; 24(5):1099-1102. PubMed ID: 29452245
[TBL] [Abstract][Full Text] [Related]
9. Bone marrow versus peripheral blood as a graft source for haploidentical donor transplantation in adults using post-transplant cyclophosphamide-A systematic review and meta-analysis.
Yu X; Liu L; Xie Z; Dong C; Zhao L; Zhang J; Gu J; Zhu HH
Crit Rev Oncol Hematol; 2019 Jan; 133():120-128. PubMed ID: 30661648
[TBL] [Abstract][Full Text] [Related]
10. Outcome of Haploidentical Peripheral Blood Allografts Using Post-Transplantation Cyclophosphamide Compared to Matched Sibling and Unrelated Donor Bone Marrow Allografts in Pediatric Patients with Hematologic Malignancies: A Single-Center Analysis.
Srinivasan A; Raffa E; Wall DA; Schechter T; Ali M; Chopra Y; Kung R; Chiang KY; Krueger J
Transplant Cell Ther; 2022 Mar; 28(3):158.e1-158.e9. PubMed ID: 34838785
[TBL] [Abstract][Full Text] [Related]
11. Haploidentical Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Post-Transplantation Cyclophosphamide Graft-versus-Host Disease Prophylaxis.
Castagna L; Mussetti A; Devillier R; Dominietto A; Marcatti M; Milone G; Maura F; de Philippis C; Bruno B; Furst S; Blaise D; Corradini P; Montefusco V
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1549-1554. PubMed ID: 28499937
[TBL] [Abstract][Full Text] [Related]
12. Treatment of hematological malignancies with nonmyeloablative, HLA-haploidentical bone marrow transplantation and high dose, post-transplantation cyclophosphamide.
Munchel AT; Kasamon YL; Fuchs EJ
Best Pract Res Clin Haematol; 2011 Sep; 24(3):359-68. PubMed ID: 21925089
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT.
van Gorkom G; van Gelder M; Eikema DJ; Blok HJ; van Lint MT; Koc Y; Ciceri F; Beelen D; Chevallier P; Selleslag D; Blaise D; Foá R; Corradini P; Castagna L; Moreno C; Solano C; Müller LP; Tischer J; Hilgendorf I; Hallek M; Bittenbring J; Theobald M; Schetelig J; Kröger N; ;
Bone Marrow Transplant; 2018 Mar; 53(3):255-263. PubMed ID: 29255169
[TBL] [Abstract][Full Text] [Related]
14. Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors.
Kanakry JA; Gocke CD; Bolaños-Meade J; Gladstone DE; Swinnen LJ; Blackford AL; Fuchs EJ; Huff CA; Borrello I; Matsui WH; Brodsky RA; Rosner GL; Shanbhag S; Luznik L; Jones RJ; Ambinder RF; Kasamon YL
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2115-2122. PubMed ID: 26183076
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Haploidentical Bone Marrow versus Matched Unrelated Donor Peripheral Blood Stem Cell Transplantation with Posttransplant Cyclophosphamide in Patients with Acute Leukemia.
Nagler A; Labopin M; Dholaria B; Angelucci E; Afanasyev B; Cornelissen JJ; Sica S; Meijer E; Ciceri F; Van Gorkom G; Kröger N; Martin H; Pioltelli P; Risitano A; Canaani J; Savani BN; Sanz J; Mohty M
Clin Cancer Res; 2021 Feb; 27(3):843-851. PubMed ID: 33148668
[TBL] [Abstract][Full Text] [Related]
16. Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation.
Kasamon YL; Fuchs EJ; Zahurak M; Rosner GL; Symons HJ; Gladstone DE; Huff CA; Swinnen LJ; Brodsky RA; Matsui WH; Borrello I; Shanbhag S; Cooke KR; Ambinder RF; Luznik L; Bolaños-Meade J; Jones RJ
Biol Blood Marrow Transplant; 2018 May; 24(5):1022-1028. PubMed ID: 29353109
[TBL] [Abstract][Full Text] [Related]
17. [CD25 monoclonal antibody for GVHD prophylaxis in non-T-cell depleted haploidentical bone marrow transplantation for treatment of childhood leukemia].
Chen HR; Ji SQ; Yan HM; Wang HX; Liu J; Xue M; Zhu L
Zhonghua Er Ke Za Zhi; 2004 Apr; 42(4):294-8. PubMed ID: 15157394
[TBL] [Abstract][Full Text] [Related]
18. Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation.
Mehta RS; Saliba RM; Chen J; Rondon G; Hammerstrom AE; Alousi A; Qazilbash M; Bashir Q; Ahmed S; Popat U; Hosing C; Khouri I; Shpall EJ; Champlin RE; Ciurea SO
Br J Haematol; 2016 May; 173(3):444-55. PubMed ID: 26947769
[TBL] [Abstract][Full Text] [Related]
19. Single-Agent Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis after Human Leukocyte Antigen-Matched Related Bone Marrow Transplantation for Pediatric and Young Adult Patients with Hematologic Malignancies.
Jacoby E; Chen A; Loeb DM; Gamper CJ; Zambidis E; Llosa NJ; Huo J; Cooke KR; Jones R; Fuchs E; Luznik L; Symons HJ
Biol Blood Marrow Transplant; 2016 Jan; 22(1):112-8. PubMed ID: 26343947
[TBL] [Abstract][Full Text] [Related]
20. Reduced Intensity Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Pediatric Inherited Immune Deficiencies and Bone Marrow Failure Syndromes.
Klein OR; Bapty S; Lederman HM; Younger MEM; Zambidis ET; Jones RJ; Cooke KR; Symons HJ
J Clin Immunol; 2021 Feb; 41(2):414-426. PubMed ID: 33159275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
